Matches in Nanopublications for { ?s ?p "[Dovitinib was then evaluated in a phase II trial that included 4 groups of patients with human EGF receptor 2-negative metastatic breast cancer on the basis of FGFR1 amplification and hormone receptor (HR) status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- NP562646.RAdGUtXYLF9wmyGZH-MXgVGehvuDiqxRclGmSPsFbOd0M130_assertion description "[Dovitinib was then evaluated in a phase II trial that included 4 groups of patients with human EGF receptor 2-negative metastatic breast cancer on the basis of FGFR1 amplification and hormone receptor (HR) status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP562646.RAdGUtXYLF9wmyGZH-MXgVGehvuDiqxRclGmSPsFbOd0M130_provenance.
- NP393522.RAJmi5vFm5_iE1SNeE9phJZ4brHMMJkg4luMMgrALa8iA130_assertion description "[Dovitinib was then evaluated in a phase II trial that included 4 groups of patients with human EGF receptor 2-negative metastatic breast cancer on the basis of FGFR1 amplification and hormone receptor (HR) status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP393522.RAJmi5vFm5_iE1SNeE9phJZ4brHMMJkg4luMMgrALa8iA130_provenance.
- NP691860.RAFEN-jA5DAHoAKB-Wv28HlWIjZ9iw_QxAPZnVZsRMLH0130_assertion description "[Dovitinib was then evaluated in a phase II trial that included 4 groups of patients with human EGF receptor 2-negative metastatic breast cancer on the basis of FGFR1 amplification and hormone receptor (HR) status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP691860.RAFEN-jA5DAHoAKB-Wv28HlWIjZ9iw_QxAPZnVZsRMLH0130_provenance.
- NP400533.RA1oWWAgfBIdhHmAKmq_fjLbTnuQMictmMFMPEEwZYvkw130_assertion description "[Dovitinib was then evaluated in a phase II trial that included 4 groups of patients with human EGF receptor 2-negative metastatic breast cancer on the basis of FGFR1 amplification and hormone receptor (HR) status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP400533.RA1oWWAgfBIdhHmAKmq_fjLbTnuQMictmMFMPEEwZYvkw130_provenance.
- assertion description "[Dovitinib was then evaluated in a phase II trial that included 4 groups of patients with human EGF receptor 2-negative metastatic breast cancer on the basis of FGFR1 amplification and hormone receptor (HR) status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Dovitinib was then evaluated in a phase II trial that included 4 groups of patients with human EGF receptor 2-negative metastatic breast cancer on the basis of FGFR1 amplification and hormone receptor (HR) status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1076272.RA9XMHSoxEQrJfGW8spRgkw6k6d38BijhxPPABiKoFp-0130_assertion description "[Dovitinib was then evaluated in a phase II trial that included 4 groups of patients with human EGF receptor 2-negative metastatic breast cancer on the basis of FGFR1 amplification and hormone receptor (HR) status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1076272.RA9XMHSoxEQrJfGW8spRgkw6k6d38BijhxPPABiKoFp-0130_provenance.